{
  "drug_name": "Colchicine",
  "url": "https://wikem.org/wiki/Colchicine",
  "scraped_at": "2026-01-10T03:10:28.128349",
  "sections": {
    "Adult_Dosing": {
      "text": "",
      "subsections": {
        "Gout": {
          "text": "Flare treatment: Initial: 1.2mg and then  0.6mg  in an hour (maximum 1.8mg within 1 hour). In patient receiving prophylaxis treatment wait for 12 h after flare dosing before resuming prophylaxis dose. Do not repeat treatment for at least 3 days (Canadian labelling recommendation)\nProphylaxis Treatment: 0.6mg twice daily (maximum 1.2mg/day) for 3 months (without tophi) to 6 months (â‰¥1 tophi) after reaching target serum uric acid levels\n[1]",
          "tables": []
        },
        "Familial_Mediterranean_Fever": {
          "text": "1.2mg to 2.4mg per day in 1-2 decided dose. Titrate (increase or decrease) 0.3mg daily increment based on efficacy and adverse effects.",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Pediatric_Dosing": {
      "text": "",
      "subsections": {
        "Familial_Mediterranean_Fever_2": {
          "text": "Children 4 to 6 years: 0.3 to 1.8mg daily in 1-2 divided doses\nChildren 6 to 12 years: 0.9 to 1.8mg daily in 1-2 divided doses\nAdolescents >12 years: Adult dosing",
          "tables": []
        },
        "Gout_2": {
          "text": "Prophylaxis/treatment: Adult dosing",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Special_Populations": {
      "text": "Pregnancy Rating\n: C\nLactation risk\n: Colchicine enters breast milk, caution should  be used when administering in a nursing woman.",
      "subsections": {
        "Renal_Dosing": {
          "text": "Adult:\nGout flare treatment:\nUse colchicine to treat acute route flare is\ncontraindicated\nin patients with renal impairment who are receiving colchicine for prophylaxis.\nCrCl 30-80 mL/minute: dose adjustment not required, monitor closely for adverse effects.\nCrCl <30 mL/minute: consider dose reduction, should not repeat dose more frequently that every 14 days.\nDialysis: A single dose of 0.6mg, should not repeat dose more frequently that every 14 days.\nGout prophylaxis:\nCrCl 30-80 mL/minute: dose adjustment not required, monitor closely for adverse effects.\nCrCl <30 mL/minute: nitial dose: 0.3mg daily, titrate with caution, monitor closely for adverse effects.\nDialysis: 0.3mg twice weekly, monitor closely for adverse effects.\nFMF:\nCrCl 30-80 mL/minute: monitor closely for adverse effects, consider dosage reduction.\nCrCl <30mL/minute: Initial dose: 0.3mg daily, titrate with caution, monitor closely for adverse effects.\nDialysis: a single dose of 0.3mg, titrate with caution, monitor closely for adverse effects.\nPediatric: Not defined",
          "tables": []
        },
        "Hepatic_Dosing": {
          "text": "Adult:\nMild to moderate impairment: use with caution, closely monitor for adverse effects.\nSevere impairment: consider dosage adjustment.\nPediatric: Not defined",
          "tables": []
        }
      },
      "tables": [],
      "links": [
        {
          "text": "Pregnancy Rating",
          "url": "https://wikem.org/wiki/Drug_Ratings_in_Pregnancy"
        },
        {
          "text": "Lactation risk",
          "url": "https://wikem.org/wiki/Lactation_risk_categories"
        }
      ]
    },
    "Contraindications": {
      "text": "Allergy to class/drug\nConcomitant use with P-glycoprotein or strong CYP3A4 inhibitor in patients with renal or hepatic impairment\nPatient with both renal and hepatic impairment\nSerious gastrointestinal or cardiac disease",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Adverse_Reactions": {
      "text": "",
      "subsections": {
        "Serious_(<1%)": {
          "text": "Bone marrow suppression\nDisseminated intravascular coagulation\nToxic neuromuscular disease\nRhabdomyolysis\nHepatotoxicity\nHypersensitivity reaction",
          "tables": []
        },
        "Common": {
          "text": "Diarrhoea\nNausea\nVomiting\nAbdominal cramp/abdominal pain\nGout\nPharyngolaryngeal pain\nFatigue\nHeadache",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Pharmacology": {
      "text": "Half-life: 27 to 31 hours (multiple dose; young, healthy volunteers)\nMetabolism: Hepatic (CYP3A4)\nExcretion: Urine",
      "subsections": {},
      "tables": [],
      "links": []
    }
  }
}